Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study
Allergy · 2025
DOI: 10.1111/all.16495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Zheng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shanghai Institute of Dermatology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan Unive…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pyrimidines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Key Project of the Innovation Program of Shanghai Municipal Education Commission, the Clinical Research Plan of Shanghai Shenkang Hospital Development Center.
Abstract (Originalsprache)
Background
Phase 3 trials have demonstrated the efficacy and safety of abrocitinib for atopic dermatitis (AD), but real‐world evidence remains limited.
Methods
This study prospectively enrolled 117 moderate‐to‐severe AD patients at Huashan Hospital, Shanghai, China. Physician‐ and patient‐reported outcomes were evaluated at multiple time points. Blood eosinophil counts, serum IgE, and 24 cytokines/chemokines were measured.
Results
Abrocitinib treatment led to rapid and potent improvements in disease severity. At week 12, 74.3% and 50.5% of AD patients achieved at least 75% and 90% improvement in the eczema area and severity index (EASI), respectively. Compared to dupilumab, abrocitinib showed greater improvement in Itch‐NRS at week 2 and a higher proportion of EASI‐75 at week 4. Adverse events occurred in 42.7% of AD patients, with gastrointestinal symptoms being the most common (17.1%). No tuberculosis (TB) reactivation was observed in patients who screened positive for TB and received isoniazid prophylaxis during the study period. Lower body mass index (BMI < 24; adjusted OR: 4.01, 95% CI: 1.36–11.73) and no prior dupilumab use (adjusted OR: 5.81, 95% CI: 1.8–18.7) were identified as predictors of a good response. By week 4, blood eosinophil counts and serum IgE significantly decreased. Reductions in Th2‐, Th1‐, and Treg‐related cytokines/chemokines after 4 weeks of abrocitinib treatment, including IL‐5, CCL17, CCL18, TNF‐α, IL‐6, IL‐10, and CD25/IL‐2Rα, were more pronounced in good responders.
Conclusion
Abrocitinib demonstrated robust efficacy and a well‐tolerated safety profile in Chinese patients with moderate‐to‐severe AD in routine clinical practice, accompanied by normalization of elevated blood biomarkers. Trial Registration ChiCRT Identifier: ChiCTR2200063195
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Shanghai Institute of Dermatology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, P.R. China.
- Department of Biostatistics, School of Public Health, and The Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.
- Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union…
ORCID-Profile: Xu Yao
Förderung
- National Natural Science Foundation of China
- the Key Project of the Innovation Program of Shanghai Municipal Education Commission
- the Clinical Research Plan of Shanghai Shenkang Hospital Development Center
- the Shanghai Municipal Commission of Health and Family Planning
- the Shanghai Municipal Key Clinical Specialty
- Shanghai Municipal Commission of Science and Technology
- the Pfizer Research Grant
- the National Key Specialty
Zitieren
APA
Li, Z., Wang, Y., Wu, Y., Yin, H., Wang, S., Wu, H., Qin, H., Wang, C., Yao, X., Li, W., & Gu, C. (2025). Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study. Allergy. https://doi.org/10.1111/all.16495
Vancouver
Li Z, Wang Y, Wu Y, Yin H, Wang S, Wu H, et al. Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study. Allergy. 2025. doi:10.1111/all.16495
BibTeX
@article{Li2025,
author = {Li, Zheng and Wang, Yu and Wu, Yuemeng and Yin, Huibin and Wang, Shangshang and Wu, Hao and Qin, Haihong and Wang, Ce and Yao, Xu and Li, Wei and Gu, Chaoying},
title = {Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16495}
}
EUVIMED